HTLV-II and bacterial infections among injection drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 5, 2000, Pages 483-487

  Safaeian, Mahboobeh ^a,b   Wilson, Lucy E ^a   Taylor, Ellen ^a   Thomas, David L ^a   Vlahov, David ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

Bacterial pneumonia; HTLV II; Incidence; Infective endocarditis; Injection drug users; Risk factors; Skin abscess

Indexed keywords

COCAINE;

ADULT; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN TISSUE; IMMUNOFLUORESCENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SKIN ABSCESS;

EID: 0034662736     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200008150-00014     Document Type: Article

References (21)

1. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia
2. The clinical epidemiology of human T-lymphotropic virus, type II (HTLV-II)
3. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia
4. Prototypical HTLV-I/II is rare in LGL leukemia
5. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis
6. Progressive spastic myelopathy in a patient co-infected with HIV-1 and HTLV-II: Autoantibodies to the human homologue of rig in blood and cerebrospinal fluid
7. Spastic ataxia associated with human T-cell lymphotropic virus type II infection
8. Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-II-endemic population
9. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection
10. A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users
11. Are HTLV-II-seropositive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy?
12. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants
13. Distinguishing between HTLV-I and HTLV-II by western blot
14. Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, U.S.A.
15. + cell count controlling for plasma HIV viral load in injection drug users in Baltimore
16. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study
17. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group
18. Seasonal and annual variation of antibody to HIV-1 among male inmates entering Maryland prisons
19. HIV infection in Baltimore: Antibody seroprevalence rates among parenteral drug abusers and prostitutes
20. Measurement of HIV risk behaviors among intravenous drug users